No products in the cart.
Roll over image to zoom in
GRAFTIDE M 500MG TABLET
₹315.00₹691.85 (-54%)
Graftide M 500mg Tablet is an immunosuppressant with an active ingredient called Mycophenolate mofetil. It belongs to the inosine monophosphate dehydrogenase (IMPDH) inhibitor category. This medicine is used to prevent organ rejection in individuals who have previously received an organ transplant (such as kidney, heart, or liver transplantation). It is prescribed as part of a combination therapy that includes other immunosuppressive drugs.
This drug is contraindicated during pregnancy due to the risk of congenital disabilities and miscarriage. It should not be advised in pregnant women unless there are no relevant alternatives and the potential benefits outweigh the risks. Women of birthing age are highly recommended to use effective contraception while taking this tablet to prevent pregnancy. Live vaccines should not be administered while a person is taking a Graftide M 500mg Tablet due to reduced vaccine effectiveness and the risk of infection. Individuals taking this drug should not donate blood during treatment and at least six weeks after stopping treatment. It ensures that the medication has been adequately cleared from the body before blood is donated.
It is generally advised not to take this medicine if you are allergic to the drug or other ingredients. Inform your doctor of liver or heart disease before initiating the treatment. As this drug reduces the body’s immune defenses, it can increase the chance of skin cancer. Individuals must take precautions to limit their exposure to sunlight and ultraviolet (UV) light. Seek your doctor immediately if you develop any bruising under the skin, fever, unexplained tiredness, dizziness, yellowing of the skin or eyes, vision impairment, reduced urine output, or seizures after taking this medicine. Graftide M 500mg Tablet is an immunosuppressive medication. It may affect the infant’s developing immune system and should be avoided in breastfeeding. Alternatively, alternative remedies with a more favorable safety profile during breastfeeding may be considered.